# Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery

> **NCT00381901** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute, France** · enrollment: 3400 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **GENETIC:** polymorphism analysis
- **PROCEDURE:** adjuvant therapy

## Key facts

- **NCT ID:** NCT00381901
- **Lead sponsor:** National Cancer Institute, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 3400 (ESTIMATED)
- **Last updated:** 2011-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00381901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00381901, "Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery". Retrieved via AI Analytics 2026-08-21 from https://api.ai-analytics.org/clinical/NCT00381901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*